[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515222":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":10,"responsibleParty":26,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":10,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":39,"enrollmentInfo":40,"targetDuration":10,"studyType":43,"phases":10,"briefSummary":44,"conditions":45,"keywords":51,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":10},{"fullName":5,"class":6},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observation group",null,"Primary IIIB-IV BRAF V600E mutated advanced non-small cell lung cancer in a population of patients with advanced lung cancer proposed to be treated with Trametinib， Dabrafenib and Asprin",[13],"Drug: Combind asprin with Trametinib and Dabrafenib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Combind asprin with Trametinib and Dabrafenib","Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg\u002Ftablet, 1 tablet\u002Ftime, QD",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"He Yong, MD","CONTACT","86-23-68757791","heyong@dphospital.tmmu.edu.cn",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yong He","Director of Department of Respiratory Diseases","100515222","evaluate-the-efficacy-and-safety-of-aspirin-in-combination-with-trametinib-and-dabrafenib-100515222",false,"NCT05988697","Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib","An Observational Phase II Study to Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib in Advanced Non-small Cell Lung Cancer Patients With BRAF V600E Mutation","Inclusion Criteria:\n\n1. Inoperable stage IIIB-IV patients with non-small cell lung cancer;\n2. BRAF V600E mutation;\n3. Dabrafenib and Trametinib are planned for treatment, and the survival period is expected to be more than 3 months;\n4. ECOG PS 0\u002F1;\n5. The diameter of the primary lesion should be at least 1cm;\n6. Previous or current aspirin treatment was allowed\n\nExclusion Criteria:\n\n1. The patient is currently receiving other anticoagulant therapy;\n2. The patient was previously treated with systemic anti-NSCLC;\n3. The patient had other positive driver mutations, including EGFR, ALK, ROS1, MET14, RET, etc.\n4. The patient had contraindications for dalafenib or trametinib and aspirin use;\n5. Patients who refused follow-up visits;","ALL","18 Years","75 Years",{"count":41,"type":42},36,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)",[46,47,48,49,50],"NSCLC","BRAF V600E Mutation","Advanced Cancer","Stage IIIB NSCLC","Stage IV NSCLC",[46,52,53,54,55,56],"Asprin","Dabrafenib","Trametinib","PFS","BRAF V600E mutation","NOT_YET_RECRUITING","2023-10-11",{"date":60,"type":61},"2023-10-12","ACTUAL",{"date":63,"type":42},"2023-11-01",{"date":65,"type":42},"2027-04-01",{"name":5,"class":6}]